According to CNBC, Johnson & Johnson is pushing into the robotic surgery market with Ottava, which received Food and Drug Administration approval this summer for use in multiple general surgery procedures. The company said the system’s smaller footprint and design features could help it win over surgeons and hospitals, while its surgery business generated $5.16 billion in revenue in the first six months of the year, up 4.3% from a year earlier. Hani Abouhalka, head of J&J’s surgery and robotics unit, said the company aims to become a leader in surgical robotics. Precedence Research projects the U.S. surgical robotics market will grow from about $4.4 billion in 2025 to $18.75 billion by 2035, while the global market is expected to rise from $14.45 billion in 2026 to about $50.29 billion by 2035. Ottava is approved for 10 general surgery procedures, and J&J said it is pursuing additional approvals in Western Europe and Japan as part of its rollout.
